Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
about
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsImmunotherapy in autoimmune type 1 diabetesCell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule.Factors in the Development of Liver Transplantation.OKT3 in the reversal of acute hepatic allograft rejection.Impact of Orthoclone OKT3 on liver transplantation.Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation.France and the early history of organ transplantationLiver transplantation in the ciclosporin era.Organ transplantation--then and nowImmunosuppression and other nonsurgical factors in the improved results of liver transplantation.The development of clinical renal transplantation.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.ORTHOCLONE OKT3 in Treatment of Allografts Rejected Under Cyclosporine-Steroid TherapyMonoclonal antibodies in clinical medicine.The French Heritage in Clinical Kidney TransplantationModulation of the human T cell response by a novel non-mitogenic anti-CD3 antibodyPhase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allograftsImmunotherapy of rheumatoid arthritis.Production of antigen-specific human IgGs by in vitro immunizationA Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral LoadsMicroRNA expression profiles in human CD3+ T cells following stimulation with anti-human CD3 antibodies.In vivo effects of monoclonal antibodies to distinct epitopes of Qa-2 antigens.Prophylactic use of OKT3 in liver transplantation. A reviewAntibody immunosuppressive therapy in solid-organ transplant: Part I.Moving to tolerance: clinical application of T regulatory cellsMechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals.Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody.Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibodyImportance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.Penetration of engineered antibody fragments into the eye.Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants.Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection
P2860
Q26830569-1C052444-EAFB-4A91-800C-5B825A020D8EQ27025619-9E10EC56-946B-435C-BE28-FD8236C9685AQ33557477-10E0F9ED-B041-405A-BFF1-BC86DEE9C569Q33993337-AAB29617-F244-4E28-84E4-8C7B2DC8B220Q33997759-ECBA088D-5B1C-469F-8DCD-369DF4EA8A82Q34146667-C1BFB6E2-E4BB-4BF9-8211-08D1559C93F6Q34219725-5AEA65AA-8AE3-4DF8-B033-D69CBCB89FE3Q34248985-B39503F7-9DAD-41F8-B55A-AD81745590CDQ34275290-9A96326B-F944-4C52-BE14-542EAFFD941DQ34286210-A3078904-DC6E-4767-9D48-2CDA4BFADAEEQ34286455-527D1167-624A-42D2-A11A-261C91067340Q34330601-7DE0207F-919A-43F0-A314-5314A3DC8EE0Q34375578-1C6664E3-A673-4AF2-84ED-996730144607Q34396283-9D4AD15D-1922-42A6-B139-7677066D004BQ34487904-777CCD66-E479-4682-AD01-75002F21C0BFQ34920118-4D887959-16DA-497B-8DCD-41DCE1B8A1C1Q35142083-EED13C68-9304-4CAC-AB98-C037BDEC71AAQ35232365-E8C3D5CB-5F40-48B2-94FF-1C900347CAC6Q35881647-957F8C14-E6A8-4E1D-96C7-C4D39ED4A079Q35934492-64B7AC9B-7914-492F-9AC4-71A4C230FFB3Q36149000-1DEE5DA4-8917-49BB-B1ED-7C5D00055105Q36307846-228C03B8-E96D-459B-A996-8D44F34A9186Q36350273-34FD74E4-BB5F-4288-B2F2-937A63210AEAQ37369621-71DA0734-905C-465B-888A-2C85B72F943EQ37691180-AC125805-4E70-4796-8CC1-028F0519F41AQ37881151-8ECB9A39-F848-42E6-8A04-DEAAC0B785C2Q39775657-059F5536-F103-4726-90BA-357331D3A4B2Q40927059-3B508612-40FA-4E63-BD64-90BC5CB96927Q41117094-91FCAC77-A656-4E59-B3C3-1A49B3577462Q42553495-5F03E7CF-201C-46B5-B930-D4DFD08EF46BQ42937245-41E3172F-E964-4F91-90F1-13E79FAB9610Q43975336-0D66C796-B727-4F1D-9076-14004F40019FQ54416335-9D576178-3DEE-4E09-B684-BB32E6E48188Q55475721-9D0BD8B4-34D2-46D4-9609-8CFE8B679E84Q56871235-60745BE9-2286-4B36-ACD3-8D36CC90F511
P2860
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh
1981年學術文章
@zh-hant
name
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
@en
type
label
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
@en
prefLabel
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
@en
P2093
P1433
P1476
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.
@en
P2093
Delmonico FL
Goldstein G
LaQuaglia MP
Russell PS
Tolkoff-Rubin N
P304
P577
1981-12-01T00:00:00Z